Osteopontin influences the invasiveness of pancreatic cancer cells and is increased in neoplastic and inflammatory conditions

Cancer Biology and Therapy

Volumn 4, Issue 7, 2005, Pages 740-746

  Kolb, A ^a   Kleeff, J ^a   Guweidhi, A ^a   Esposito, I ^a   Giese, N A ^a   Adwan, H ^b   Giese, T ^a   Buchler M W ^a   Berger, M R ^b   Friess, H ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Extracellular matrix; Glycoprotein; Invasion; Metastasis; Pancreatic cancer; Serum marker

Indexed keywords

OSTEOPONTIN; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PANCREAS CARCINOMA; PROGNOSIS; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH;

EID: 25144492709     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.7.1821     Document Type: Article

References (34)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ and Thun MJ. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
2. Rosty C and Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am 2002; 16:37-52.
3. Friess H, Ding J, Kleeff J, Fenkell L, Rosinski JA, Guweidhi A, Reidhaar-Olson JF, Korc M, Hammer J and Buchler MW. Microarray-based identification of differentially expressed growth and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci 2003; 60:1180-99.
4. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB and Von Hoff DD. Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 2002; 62:2890-6.
5. Denhardt DT and Guo X. Osteopontin: a protein with diverse functions. FASEB J 1993; 7:1475-82.
6. Xuan JW, Hota C, Shigeyama Y, D'Errico JA, Somerman MJ and Chambers AF. Site-directed mutagenesis of the arginine-glycine-aspartic acid sequence in osteopontin destroys cell adhesion and migration functions. J Cell Biochem 1995; 57:680-90.
7. Patarca R, Saavedra RA and Cantor H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit Rev Immunol 1993; 13:225-46.
8. Scatena M and Giachelli C. The alpha(v)beta3 integrin, NF-kappaB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. Trends Cardiovasc Med 2002; 12:83-8.
9. Young MF, Kerr JM, Termine JD, Wewer UM, Wang MG, McBride OW and Fisher LW. cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 1990; 7:491-502.
10. Humphries MJ, Olden K and Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 1986; 233:467-70.
11. Seftor RE, Seftor EA, Gehlsen KR, Stetler-Stevenson WG, Brown PD, Ruoslahti E and Hendrix MJ. Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 1992; 89:1557-61.
12. Brown LF, Papadopoulos-Sergiou A, Berse B, Manseau EJ, Tognazzi K, Perruzzi CA, Dvorak HF and Senger DR. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994; 145:610-23.
13. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF and Yeatman TJ. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004; 10:184-90.
14. Hotte SJ, Winquist EW, Stitt L, Wilson SM and Chambers AF. Plasma osteopontin: associations with survival and metastasis to bone in men with hormone-refractory prostate carcinoma. Cancer 2002; 95:506-12.
15. Le QT, Sutphin PD, Raychaudhuri S, Yu SC, Terris DJ, Lin HS, Lum B, Pinto HA, Koong AC and Giaccia AJ. Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res 2003; 9:59-67.
16. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL and Hsu HC. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 2003; 98:119-27.
17. Rudland PS, Platt-Higgins A, El Tanani M, De Silva RS, Barraclough R, Winstanley JH, Howitt R and West CR. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002; 62:3417-27.
18. Schneider S, Yochim J, Brabender J, Uchida K, Danenberg KD, Metzger R, Schneider PM, Salonga D, Holscher AH and Danenberg PV. Osteopontin but not osteonectin messenger RNA expression is a prognostic marker in curatively resected non-small cell lung cancer. Clin Cancer Res 2004; 10:1588-96.
19. Hirama M, Takahaski F, Takahashi K, Akutagawa S, Shimizu K, Soma S, Shimanuki Y, Nishio K and Fukuchi Y. Osteopontin overproduced by tumor cells acts as a potent angiogenic factor contributing to tumor growth. Cancer Lett 2003; 198:107-17.
20. Oates AJ, Barraclough R and Rudland PS. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 1996; 13:97-104.
21. Oates AJ, Barraclough R, and Rudland PS. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 1997; 17:1-15.
22. Koopmann J, Fedarko NS, Jain A, Maitra A, Iacobuzio-Donahue C, Rahman A, Hruban RH, Yeo CJ and Goggins M. Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2004; 13:487-91.
23. Guo J, Kleeff J, Li J, Ding J, Hammer J, Zhao Y, Giese T, Korc M, Buchler MW and Friess H. Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene 2004; 23:71-81.
24. Kleeff J and Korc M. Up-regulation of transforming growth factor (TGF)-beta receptors by TGF-beta1 in COLO-357 cells. J Biol Chem 1998; 273:7495-500.
25. Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haussmann I, Matzku S, Wenzel A, Ponta H and Herrlich P. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991; 65:13-24.
26. Seiter S, Arch R, Reber S, Komitowski D, Hofmann M, Ponta H, Herrlich P, Matzku S and Zoller M. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 1993; 177:443-55.
27. Standal T, Hjorth-Hansen H, Rasmussen T, Dahl IM, Lenhoff S, Brenne AT, Seidel C, Baykov V, Waage A, Borset M, Sundan A and Hjertner O. Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma. Haematologica 2004; 89:174-82.
28. Gassler N, Autschbach F, Gauer S, Bohn J, Sido B, Otto HF, Geiger H and Obermuller N. Expression of osteopontin (Eta-1) in Crohn disease of the terminal ileum. Scand.J Gastroenterol 2002; 37:1286-95.
29. Li C, Yang CW, Ahn HJ, Kim WY, Park CW, Park JH, Cha JH, Kim J, Kim YS and Bang BK. Colchicine suppresses osteopontin expression and inflammatory cell infiltration in chronic cyclosporine nephrotoxicity. Nephron 2002; 92:422-30.
30. Noda M and Rodan GA. Type beta transforming growth factor regulates expression of genes encoding bone matrix proteins. Connect Tissue Res 1989; 21:71-5.
31. Sodhi CP, Phadke SA, Batlle D and Sahai A. Hypoxia stimulates osteopontin expression and proliferation of cultured vascular smooth muscle cells: potentiation by high glucose. Diabetes 2001; 50:1482-90.
32. Murray D, Morrin M and McDonnell S. Increased invasion and expression of MMP-9 in human colorectal cell lines by a CD44-dependent mechanism. Anticancer Res 2004; 24:489-94.
33. Omara-Opyene AL, Qiu J, Shah GV and Iczkowski KA. Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18. Lab Invest 2004;
34. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF and Harris JF. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997; 3:605-11.